Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MACKNASDAQ:MYGNNASDAQ:RGLSNASDAQ:ZBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMACKMerrimack Pharmaceuticals$15.13$14.82$11.53▼$15.89$223.77M1.45396,929 shsN/AMYGNMyriad Genetics$5.19+2.0%$6.10$3.81▼$29.30$478.40M1.841.21 million shs2.16 million shsRGLSRegulus Therapeutics$8.30+1.0%$5.48$0.83▼$8.64$569.10M0.35931,351 shs1.48 million shsZBIOZenas Biopharma$11.92+7.2%$9.59$5.83▼$26.25$498.66MN/A181,284 shs184,441 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMACKMerrimack Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MYGNMyriad Genetics+1.96%+16.37%+33.42%-49.37%-76.56%RGLSRegulus Therapeutics+0.97%+4.53%+5.46%+524.06%+272.20%ZBIOZenas Biopharma+7.19%+18.49%+31.71%+1,191,999,900.00%+1,191,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMYGNMyriad Genetics4.0541 of 5 stars4.11.00.04.12.11.70.6RGLSRegulus Therapeutics2.2616 of 5 stars2.15.00.00.02.93.30.0ZBIOZenas Biopharma1.4068 of 5 stars3.50.00.00.01.70.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMACKMerrimack Pharmaceuticals 0.00N/AN/AN/AMYGNMyriad Genetics 2.13Hold$14.38177.16% UpsideRGLSRegulus Therapeutics 2.29Hold$8.502.41% UpsideZBIOZenas Biopharma 3.00Buy$36.67207.61% UpsideCurrent Analyst Ratings BreakdownLatest MACK, MYGN, RGLS, and ZBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025MYGNMyriad GeneticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$20.00 ➝ $6.005/16/2025ZBIOZenas BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/15/2025MYGNMyriad GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.50 ➝ $9.005/15/2025ZBIOZenas BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$35.005/8/2025MYGNMyriad GeneticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Peer Perform5/7/2025MYGNMyriad GeneticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$18.005/7/2025MYGNMyriad GeneticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $8.005/7/2025MYGNMyriad GeneticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$19.00 ➝ $10.005/7/2025MYGNMyriad GeneticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$16.00 ➝ $7.005/7/2025MYGNMyriad GeneticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$22.00 ➝ $6.005/1/2025RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$9.00(Data available from 6/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMACKMerrimack PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/AMYGNMyriad Genetics$831.30M0.58N/AN/A$9.53 per share0.54RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.05 per shareN/AZBIOZenas Biopharma$15M33.24N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMACKMerrimack Pharmaceuticals-$1.18M$13.871.09∞N/AN/A-1.93%-1.78%N/AMYGNMyriad Genetics-$263.30M-$1.12N/AN/AN/A-14.09%-4.51%-3.07%8/5/2025 (Estimated)RGLSRegulus Therapeutics-$30.04M-$0.73N/AN/AN/AN/A-53.07%-48.58%8/6/2025 (Estimated)ZBIOZenas BiopharmaN/A-$3.55N/A∞N/AN/AN/AN/A8/21/2025 (Estimated)Latest MACK, MYGN, RGLS, and ZBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ZBIOZenas Biopharma-$1.15-$0.80+$0.35-$0.80$5.00 million$10.00 million5/8/2025Q1 2025RGLSRegulus Therapeutics-$0.29-$0.15+$0.14-$0.15N/AN/A5/6/2025Q1 2025MYGNMyriad Genetics-$0.05-$0.03+$0.02N/A$200.37 million$195.90 million3/20/2025Q4 2024RGLSRegulus Therapeutics-$0.20-$0.20N/A-$0.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/AZBIOZenas Biopharma$0.050.40%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMACKMerrimack PharmaceuticalsN/A10.7810.78MYGNMyriad Genetics0.051.901.73RGLSRegulus TherapeuticsN/A14.1514.14ZBIOZenas BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMACKMerrimack Pharmaceuticals63.97%MYGNMyriad Genetics99.02%RGLSRegulus Therapeutics92.38%ZBIOZenas BiopharmaN/AInsider OwnershipCompanyInsider OwnershipMACKMerrimack Pharmaceuticals30.57%MYGNMyriad Genetics2.40%RGLSRegulus Therapeutics4.35%ZBIOZenas Biopharma16.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMACKMerrimack Pharmaceuticals42614.79 million10.27 millionOptionableMYGNMyriad Genetics2,60092.18 million89.12 millionOptionableRGLSRegulus Therapeutics3069.23 million62.65 millionOptionableZBIOZenas BiopharmaN/A41.83 millionN/AN/AMACK, MYGN, RGLS, and ZBIO HeadlinesRecent News About These CompaniesLevi & Korsinsky Urges Zenas BioPharma, Inc. (ZBIO) Shareholders to Act Before Lead Plaintiff Deadline June 16, 2025June 10 at 7:15 AM | accessnewswire.comZBIO Stockholders Have Opportunity to Lead Zenas BioPharma, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!June 10 at 7:00 AM | accessnewswire.comZenas BioPharma, Inc. Class Action: Levi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIOJune 10 at 5:45 AM | prnewswire.comThe Gross Law Firm Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit ...June 10 at 2:00 AM | reflector.comThe Gross Law Firm Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit ...June 10 at 2:00 AM | reflector.comShareholders of Zenas BioPharma, Inc. (ZBIO): Protect Your Rights Before June 16, 2025 - Contact Levi & KorsinskyJune 9 at 9:30 PM | accessnewswire.comSecurities Fraud Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) - Levi & Korsinsky Reminds Investors of June 16, 2025June 9 at 4:45 PM | accessnewswire.comZBIO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by The Firm - ZBIOJune 9 at 4:15 PM | accessnewswire.comThe Gross Law Firm Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 – ZBIOJune 9 at 1:34 PM | globenewswire.comInvestors in Zenas BioPharma, Inc. (ZBIO): Protect Your Rights - Contact Levi & Korsinsky Before June 16, 2025June 9 at 11:15 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIOJune 9 at 10:40 AM | accessnewswire.comClass Action Lawsuit Alert: Levi & Korsinsky Reminds Zenas BioPharma, Inc. (ZBIO) Investors of June 16, 2025 DeadlineJune 9 at 10:30 AM | accessnewswire.comZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law FirmJune 9 at 10:10 AM | prnewswire.comClass Action Lawsuit Filed Against Zenas BioPharma, Inc. (ZBIO) - Recover Losses - Contact Levi & Korsinsky Before June 16, 2025June 9 at 8:50 AM | accessnewswire.comInvestor Alert: Deadline Approaching to Join Zenas BioPharma, Inc. (ZBIO) Class Action - Contact Levi & KorsinskyJune 9 at 7:30 AM | accessnewswire.comZBIO Shareholders Have Opportunity to Lead Zenas BioPharma, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!June 9 at 7:00 AM | accessnewswire.comLevi & Korsinsky Notifies Zenas BioPharma, Inc. (ZBIO) Investors - Lead Plaintiff Deadline on June 16, 2025June 9 at 5:45 AM | accessnewswire.comShareholders that lost money on Zenas BioPharma, Inc.(ZBIO) should contact The Gross Law Firm about pending Class Action - ZBIOJune 9 at 5:45 AM | prnewswire.comZBIO INVESTOR NOTICE: Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitJune 9 at 5:30 AM | prnewswire.comJune 16, 2025 Deadline: Join Class Action Lawsuit Against Zenas BioPharma, Inc. (ZBIO) - Contact Levi & KorsinskyJune 8 at 6:45 PM | accessnewswire.comZenas Biopharma Inc (NASDAQ:ZBIO) Shares Sold by Wellington Management Group LLPJune 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMACK, MYGN, RGLS, and ZBIO Company DescriptionsMerrimack Pharmaceuticals NASDAQ:MACKMerrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.Myriad Genetics NASDAQ:MYGN$5.19 +0.10 (+1.96%) Closing price 06/9/2025 04:00 PM EasternExtended Trading$5.20 +0.00 (+0.10%) As of 09:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Regulus Therapeutics NASDAQ:RGLS$8.30 +0.08 (+0.97%) Closing price 06/9/2025 04:00 PM EasternExtended Trading$8.64 +0.34 (+4.08%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Zenas Biopharma NASDAQ:ZBIO$11.92 +0.80 (+7.19%) As of 06/9/2025 04:00 PM EasternZenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robinhood Drops on S&P Snub—Is a Bigger Pullback Coming? 3 Tightly-Held Growth Stocks Set Up for Short Squeezes Palantir Stock Holds Support, Despite Political Backlash Science Applications International Is a Wicked Hot Buy in June Why Unity Software May Be the AI Breakout No One Saw Coming Tesla Stock Dips to Buy Zone—Robotaxi Catalyst Ahead? Is Lululemon’s 18% Selloff Overdone? Analysts Say Yes MarketBeat Week in Review – 06/02 - 06/06 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
